NeOnc Technologies Holdings, Inc. Joins Russell Microcap庐 Index
NeOnc Technologies Holdings (NASDAQ: NTHI), a clinical-stage biopharmaceutical company developing CNS cancer treatments, has been added to the Russell Microcap庐 Index following its 2025 annual reconstitution. This inclusion positions NTHI among select companies with market caps between $30 million and $3 billion, representing less than 3% of the U.S. equity market.
The company is currently advancing two Phase II clinical trials with its proprietary NEO100鈩� and NEO212鈩� therapeutics, both operating under FDA Fast-Track and IND status. NeOnc's drug development platform focuses on overcoming blood-brain barrier challenges, with patent protections extending to 2038. The company is also pursuing strategic expansion in the MENA region through a proposed partnership with Quazar in the GCC.
NeOnc Technologies Holdings (NASDAQ: NTHI), una societ脿 biofarmaceutica in fase clinica che sviluppa trattamenti per il cancro del sistema nervoso centrale, 猫 stata inclusa nel Russell Microcap庐 Index a seguito della ristrutturazione annuale del 2025. Questa inclusione colloca NTHI tra le aziende selezionate con capitalizzazioni di mercato comprese tra 30 milioni e 3 miliardi di dollari, rappresentando meno del 3% del mercato azionario statunitense.
La societ脿 sta attualmente portando avanti due studi clinici di Fase II con i suoi farmaci proprietari NEO100鈩� e NEO212鈩�, entrambi in regime di Fast-Track FDA e con status IND. La piattaforma di sviluppo farmaceutico di NeOnc si concentra sul superamento delle barriere emato-encefaliche, con protezioni brevettuali valide fino al 2038. L'azienda sta inoltre perseguendo un'espansione strategica nella regione MENA tramite una proposta di partnership con Quazar nel GCC.
NeOnc Technologies Holdings (NASDAQ: NTHI), una empresa biofarmac茅utica en etapa cl铆nica que desarrolla tratamientos para el c谩ncer del sistema nervioso central, ha sido a帽adida al Russell Microcap庐 Index tras la reconstituci贸n anual de 2025. Esta inclusi贸n posiciona a NTHI entre compa帽铆as seleccionadas con capitalizaciones de mercado entre 30 millones y 3 mil millones de d贸lares, representando menos del 3% del mercado accionario estadounidense.
La empresa est谩 avanzando actualmente en dos ensayos cl铆nicos de Fase II con sus terapias propietarias NEO100鈩� y NEO212鈩�, ambas bajo la designaci贸n Fast-Track de la FDA y con estatus IND. La plataforma de desarrollo de f谩rmacos de NeOnc se enfoca en superar las barreras hematoencef谩licas, con protecciones de patentes vigentes hasta 2038. Adem谩s, la compa帽铆a busca una expansi贸n estrat茅gica en la regi贸n MENA mediante una propuesta de asociaci贸n con Quazar en el GCC.
NeOnc Technologies Holdings (NASDAQ: NTHI)電� 欷戩稊鞁犼步瓿� 鞎� 旃橂鞝滊ゼ 臧滊皽頃橂姅 鞛勳儊 雼硠鞚� 氚旍澊鞓れ牅鞎� 須岇偓搿�, 2025雲� 鞐半 鞛惮靹� 鞚错泟 Russell Microcap庐 Index鞐� 韼胳瀰霅橃棃鞀惦媹雼�. 鞚� 韽暔鞙茧 NTHI電� 鞁滉皜齑濎暋 3觳滊 雼煬鞐愳劀 30鞏� 雼煬 靷澊鞚� 靹犾爼霅� 旮办梾 欷� 頃橂倶臧� 霅橃棃鞙茧┌, 氙戈淡 欤检嫕 鞁滌灔鞚� 3% 氙鸽鞚� 彀頃╇媹雼�.
須岇偓電� 順勳灛 FDA 韺姢韸疙姼霝� 氚� IND 靸來儨 頃橃棎 鞛愳泊 臧滊皽頃� NEO100鈩� 氚� NEO212鈩� 旃橂鞝� 霊� 臧�歆�鞚� 2靸� 鞛勳儊 鞁滍棙鞚� 歆勴枆 欷戩瀰雼堧嫟. NeOnc鞚� 鞎诫 臧滊皽 頂岆灚韽检潃 順堨暋雵岇灔氩� 氍胳牅毳� 攴闺车頃橂姅 雿� 欷戩爯鞚� 霊愱碃 鞛堨溂氅�, 韸鬼棃 氤错樃電� 2038雲勱箤歆� 鞙犿毃頃╇媹雼�. 霕愴暅 GCC 歆�鞐潣 Quazar鞕�鞚� 鞝滍湸毳� 韱淀暣 MENA 歆�鞐棎靹� 鞝勲灥鞝� 頇曥灔鞚� 於旍頃橁碃 鞛堨姷雼堧嫟.
NeOnc Technologies Holdings (NASDAQ: NTHI), une soci茅t茅 biopharmaceutique en phase clinique d茅veloppant des traitements contre les cancers du syst猫me nerveux central, a 茅t茅 ajout茅e au Russell Microcap庐 Index suite 脿 sa reconstitution annuelle de 2025. Cette inclusion place NTHI parmi une s茅lection d鈥檈ntreprises dont la capitalisation boursi猫re se situe entre 30 millions et 3 milliards de dollars, repr茅sentant moins de 3 % du march茅 boursier am茅ricain.
L鈥檈ntreprise m猫ne actuellement deux essais cliniques de Phase II avec ses th茅rapeutiques propri茅taires NEO100鈩� et NEO212鈩�, toutes deux b茅n茅ficiant du statut Fast-Track de la FDA et du statut IND. La plateforme de d茅veloppement de m茅dicaments de NeOnc se concentre sur le d茅passement de la barri猫re h茅mato-enc茅phalique, avec des protections par brevet jusqu鈥檈n 2038. La soci茅t茅 poursuit 茅galement une expansion strat茅gique dans la r茅gion MENA via un partenariat propos茅 avec Quazar dans le GCC.
NeOnc Technologies Holdings (NASDAQ: NTHI), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das Behandlungen f眉r ZNS-Krebs entwickelt, wurde im Rahmen der j盲hrlichen Neuzusammensetzung 2025 in den Russell Microcap庐 Index aufgenommen. Diese Aufnahme positioniert NTHI unter ausgew盲hlten Unternehmen mit Marktkapitalisierungen zwischen 30 Millionen und 3 Milliarden US-Dollar, was weniger als 3 % des US-Aktienmarktes entspricht.
Das Unternehmen f眉hrt derzeit zwei Phase-II-Studien mit seinen propriet盲ren Therapeutika NEO100鈩� und NEO212鈩� durch, die beide den FDA Fast-Track-Status und IND-Status besitzen. Die Wirkstoffentwicklungsplattform von NeOnc konzentriert sich darauf, die Blut-Hirn-Schranke zu 眉berwinden, mit Patentschutz bis 2038. Zudem strebt das Unternehmen eine strategische Expansion in der MENA-Region durch eine vorgeschlagene Partnerschaft mit Quazar im GCC an.
- Inclusion in Russell Microcap庐 Index, providing exposure to $10.6 trillion in benchmarked assets
- Two drug candidates (NEO100鈩� and NEO212鈩�) in Phase II trials with FDA Fast-Track status
- Patent protection extending to 2038 for proprietary technology
- Strategic expansion potential through proposed Quazar partnership in GCC region
- Early clinical-stage company with no commercialized products yet
- Uncertainty regarding final terms of Quazar partnership
- Potential risks associated with clinical trial outcomes
Insights
NeOnc's Russell Microcap inclusion provides increased visibility and passive fund flows, potentially improving liquidity for this clinical-stage CNS company.
NeOnc Technologies' inclusion in the Russell Microcap Index represents a significant milestone that brings several tangible benefits to the company and its shareholders. This index reconstitution occurs annually and captures the bottom 2-3% of the total US equity market by capitalization.
The inclusion delivers three key advantages:
- Enhanced visibility among institutional investors who use Russell indexes as benchmarks
- Automatic buying pressure from passive index funds (~
$10.6 trillion in assets benchmark against Russell indexes) - Improved trading liquidity and volume
For a clinical-stage biopharmaceutical company like NeOnc, which is advancing Phase II trials for CNS cancer treatments, this index inclusion provides valuable market recognition at a critical development stage. The Russell Microcap typically includes companies with market caps between
While the index inclusion itself doesn't change NeOnc's fundamental business outlook, it represents external validation and creates a technical tailwind through increased institutional awareness and potential passive investment flows. The company's clinical assets, particularly NEO100鈩� and NEO212鈩� therapeutics currently in Phase II trials with FDA Fast-Track designation, remain the primary value drivers. The index membership will remain in place for one year until the next annual reconstitution.
CALABASSAS, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biopharmaceutical company focused on innovative treatments for central nervous system (CNS) cancers and disorders, has joined the Russell Microcap庐 Index following the conclusion of the 2025 Russell indexes annual reconstitution.
The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks ranking them by total market capitalization. Membership in the Russell Microcap庐 Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.
鈥淛oining the Russell Microcap庐 Index is a powerful validation of NeOnc鈥檚 momentum and our unwavering commitment to shareholder value and patient impact,鈥� said Amir Heshmatpour, Executive Chairman and President of NeOnc Technologies Holdings, Inc. 鈥淭his index represents microcap companies with an average market cap of about
Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Russell's US indexes serve as the benchmark for about
For more information on the Russell Microcap庐 Index and the Russell indexes reconstitution, go to the "Russell Reconstitution" section on the FTSE Russell website.
ABOUT NEONC TECHNOLOGIES HOLDINGS, INC.
NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company focused on the development and commercialization of central nervous system therapeutics that are designed to address the persistent challenges in overcoming the blood-brain barrier. The company鈥檚 NEO鈩� drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038. These proprietary chemotherapy agents have demonstrated positive effects in laboratory tests on various types of cancers and in clinical trials treating malignant gliomas. NeOnc鈥檚 NEO100鈩� and NEO212鈩� therapeutics are in Phase II human clinical trials and are advancing under FDA Fast-Track and Investigational New Drug (IND) status. The company has exclusively licensed an extensive worldwide patent portfolio from the University of Southern California consisting of issued patents and pending applications related to NEO100, NEO212, and other products from the NeOnc patent family for multiple uses, including oncological and neurological conditions.
For more about NeOnc and its pioneering technology, visit听.
Important Cautions Regarding Forward Looking Statements
This press release contains 鈥渇orward-looking statements鈥� within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by terminology such as 鈥渕ay,鈥� 鈥渨ill,鈥� 鈥渟hould,鈥� 鈥渋ntend,鈥� 鈥渆xpect,鈥� 鈥減lan,鈥� 鈥渂udget,鈥� 鈥渇orecast,鈥� 鈥渁nticipate,鈥� 鈥渂elieve,鈥� 鈥渆stimate,鈥� 鈥減redict,鈥� 鈥減otential,鈥� 鈥渃ontinue,鈥� 鈥渆valuating,鈥� or similar words. Statements that contain these words should be read carefully, as they discuss our future expectations, projections of future results of operations or financial condition, or other forward-looking information.
Examples of forward-looking statements include, among others, statements regarding whether a definitive agreement will be reached with Quazar. These statements reflect our current expectations based on information available at this time, but future events may differ materially from those anticipated.
The 鈥淩isk Factors鈥� section of our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, along with other cautionary language in that report or in our subsequent filings, outlines important risks and uncertainties. These may cause our actual results to differ materially from the forward-looking statements herein, including but not limited to the failure to finalize the agreement with Quazar, modifications to its terms, or alternative uses of proceeds.
We assume no obligation to revise or update any forward-looking statements, whether as a result of new information, future developments, or otherwise, except as required by applicable securities laws and regulations.
鈥淣EO100鈥� and NEO 鈥�212鈥� are registered trademarks of NeOnc Technologies Holdings, Inc.
Company Contact:鈥ㄢ��
Investor Contact:鈥ㄢ��
James Carbonara鈥�
Hayden IR鈥�
646)-755-7412鈥�
听
FAQ
What does NeOnc Technologies' (NTHI) inclusion in the Russell Microcap Index mean for investors?
What are the main products in NeOnc Technologies' (NTHI) clinical pipeline?
How long does NeOnc Technologies' (NTHI) patent protection extend?
What is NeOnc Technologies' (NTHI) expansion strategy in the MENA region?
What is the focus of NeOnc Technologies' (NTHI) drug development platform?
